CHMMF (Chimeric Therapeutics) GF Score: 13/100 (As of Jun. 30, 2026) — 28% Below Median


CHMMF Chimeric Therapeutics Ltd CHMMF
13 GF Score
Price $0.10
! 1 Warning Sign
View Full Analysis

What is Chimeric Therapeutics GF Score?

Chimeric Therapeutics CHMMF -96.67% 13 GF Score is 13 as of Jun. 30, 2026, which is 28% below its 10-year median of 18.00. GuruFocus rates CHMMF with a GF Score™ of 13/100. The stock has 1 warning sign investors should review.

Chimeric Therapeutics has the GF Score of 13, which implies that the company might have Worst future performance potential, or not enough data.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 4/10
2. Profitability Rank : 1/10
3. Growth Rank : 0/10
4. GF Value Rank : 0/10
5. Momentum Rank : 1/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes Chimeric Therapeutics might have Worst future performance potential, or not enough data.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Chimeric Therapeutics  (OTCPK:CHMMF) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score Performance Potential and All-in-One Screener Examples (1)
91 - 100Highest outperformance potential
81 - 90Good outperformance potential
71 - 80Likely to have average performance
51 - 70Poor future performance potential
0 - 50Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.

Chimeric Therapeutics GF Score Related Terms

CHMMF vs VRTX, REGN, ALNY: GF Score Comparison

For the Biotechnology subindustry, Chimeric Therapeutics's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Chimeric Therapeutics GF Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chimeric Therapeutics's GF Score distribution charts can be found below:

* The bar in red indicates where Chimeric Therapeutics's GF Score falls into.


CHMMF
13GF Score
Chimeric Therapeutics Ltd CHMMF
GF Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Score →
What does a GF Score of 13 mean?
Chimeric Therapeutics (CHMMF) has a GF Score of 13 as of Jun. 30, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Chimeric Therapeutics and its competitors. This is 28% below median its historical median of 18.00. Over the past decade, Chimeric Therapeutics' GF Score has ranged from 13.00 to 22.00.
Is Chimeric Therapeutics' GF Score too high?
Chimeric Therapeutics' current GF Score of 13 is 28% below median its 10-year median of 18.00. Over the past 10 years, this metric has ranged from a low of 13.00 to a high of 22.00. Overall, Chimeric Therapeutics has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Chimeric Therapeutics' GF Score compare to VRTX and REGN?
Chimeric Therapeutics' GF Score of 13 can be compared against companies in the Biotechnology industry. Historically, Chimeric Therapeutics' own GF Score has ranged from 13.00 to 22.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Biotechnology company?
A good GF Score depends on the Biotechnology industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Chimeric Therapeutics and its competitors. Chimeric Therapeutics's current GF Score is 13, which is 28% below median its own 10-year median of 18.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chimeric Therapeutics stock overvalued right now?
Chimeric Therapeutics (CHMMF) has a current GF Score of 13. The current GF Score is 13, which is 28% below median its 10-year median of 18.00. Chimeric Therapeutics' overall GF Score™ is 13/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Chimeric Therapeutics (CHMMF), the current GF Score is 13 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Chimeric Therapeutics Business Description

Other Exchanges CHM:Australia
Address 62 Lygon Street, Level 3, Carlton, Melbourne, VIC, AUS, 3053
Chimeric Therapeutics Ltd is an Australian clinical-stage cell therapy company focused on developing and commercialising a range of cell therapies in oncology. The group's products under development include T Cell Derived Autologous Therapies and Natural Killer (NK) Cell Derived Allogenic Therapies. T Cell Derived Autologous therapy works by engineering the T cells with the exact coordinates to attack and kill cancer. NK Cell Derived Allogenic Therapies from healthy donors can be manufactured on a large scale and, once administered, kill cancer. Its pipeline products include CDH17, CLTX, and CORE NK. The group has one reportable segment, being the research, development, and commercialisation of health technologies.
13GF Score

Get the complete analysis for CHMMF

GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.10
Price